Medmix Ag · SIX:MEDX
Medmix — H1 2025 Earnings Presentation
24 slides from Medmix's earnings presentation, Jul 23, 2025
Slide 1: Half-Year results 2025
Half-Year results 2025 René Willi, CEO Jennifer Dean, CFO July 23, 2025 Providing innovative solutions to help people live healthier and more confident lives
Slide 2: Disclaimer and important notes / Safe harbor statement
Disclaimer and important notes / Safe harbor statement under the US private securities litigation reform act 1995 This presentation contains forward-looking statements that are based on management’s current assumptions and expectations concerning future developments, including but not limited to, pr
Slide 3: Highlights and Business Review
Highlights and Business Review René Willi, CEO C system (ErgoSyringe): an intuitive solution for delivery of biomaterials
Slide 4: Increased profitability despite subdued revenues
Increased profitability despite subdued revenues Key Figures Half-Year 2025 Group Strong Adjusted Revenues1 EBITDA margin up 80 bps YoY ONCF slightly below YoY to 19.9% 225.4 due to inventory build up to mitigate tariffs impact and EBIT up at 15.7 and EBIT as % of improve service level for US -6.5%
Slide 5: Business unit revenue and key drivers
Business unit revenue and key drivers Healthcare Segment Consumer & Industrial (C&I) Segment Drug Dental Surgery Industry Beauty Delivery 59.9 19.9 8.3 63.5 73.8 +10.1% -4.9% +26.1% -1.3% -17.7% • Market share gains • H1 25 is missing non- • Low comparable H1 24 • Growth lower YoY, but • Project del
Slide 6: Financial Review
Financial Review Jennifer Dean, CFO MIXPACTM greenLine B-System for two-component industrial applications
Slide 7: Key performance indicators
Key performance indicators Improved profitability despite subdued revenues CHF million HY 2025 HY 2024 change • Group revenues declined YoY by -6.5% on a Revenue 225.4 241.2 -6.5% reported basis and by -4.6% organically. Organic revenue growth – – -4.6% Segment gross profit 107.9 106.2 +1.6% • Segme
Slide 8: Strong growth in strategic healthcare segment
Strong growth in strategic healthcare segment -6.5% -4.6% organic Business Units % 6 2 share of Revenue 241 (1) (1) (16) 230 (5) 226 32% 28% 4% 9% % Change in organic growth 27% +10.1% +26.1% -4.9% -1.3% -17.7% Revenue Dental Drug Drug Delivery Industry Beauty Organic FX FX effect Revenue H1 2025 Re
Slide 9: Improved GP margin through Growth and Efficiency Program
Improved GP margin through Growth and Efficiency Program Healthcare segment gross profit C&I segment gross profit 56.0 63.0% 56.0 40.0% 54.0 54.0 CHF million CHF million 52.0 52.0 Margin Margin 62.0% 35.0% 50.0 50.0 48.0 48.0 46.0 61.0% 46.0 30.0% HY 24 HY 25 HY 24 HY 25 CHF million % margin CHF mil
Slide 10: Growth and Efficiency Program delivers improved profitability
Growth and Efficiency Program delivers improved profitability Higher Dental in mix Industry & Beauty Lower YoY non-ops margin improvement and amortization Margin grown YoY 19.1% 0.9 add-backs 19.9% and sequentially 7.1 46.0 0.1 (4.0) 44.9 Lower OPEX due to (5.3) high R&D project work and end of Beau
Slide 11: EBIT % of revenues
EBIT Positively impacted by segment Gross margin growth 10.0% 15.0 10.0 • EBIT at CHF 15.7m (+22.2% YoY) and EBIT as % % of revenues of revenues at 7.0% (+170 bps YoY) CHF million 5.0% • Growth and Efficiency initiatives driving higher 5.0 Dental in mix and Industry & Beauty profitability gains - 0.
Slide 12: Operating net cash flow bridge
Operating net cash flow bridge Inventory increase in Dental to improve US customers service levels 0.1 20.1 (0.4) (4.5) 15.3 ONCF ONCF H1 2024 H1 2025 Chart figures in CHF millions 12
Slide 13: Strategy & Outlook
Strategy & Outlook MIXPACTM 1ml: syringe with dispensing tip for storage, dispensing and application of dental materials
Slide 14: Strategic Priorities To Ensure Sustainable Growth
Strategic Priorities To Ensure Sustainable Growth 1 Transform medmix into a high-performance organization Healthcare Segment: Dental – Portfolio optimization 6 2 Create the next generation of dental applicators Healthcare Segment: Surgery – C&I segment – 5 3 Becoming a strategic partner Expand margi
Slide 15: Growth & Efficiency Program: positively impacting profitability
Growth & Efficiency Program: positively impacting profitability H1 2025 cost-out ahead of plan 33 3 30 • Beauty Efficiency program: acceleration 9 of cost out initiatives CHF 1m secured savings • Additional CHF 3m savings (out of CHF 9m) • Automation projects 17 • Supply chain optimization CHF 11m s
Slide 16: Tariffs: well positioned to mitigate impact
Tariffs: well positioned to mitigate impact Global footprint and strong customer relationships Beauty, Surgery Some Industry US customers & Drug Delivery production Some Dental US customer served through local-for-local in Atlanta and served through Haag (CH) site Valencia and China sites Elgin site
Slide 17: Capital Allocation Principles
Capital Allocation Principles Maintain strong balance sheet Innovation: Accelerate development of next generation applicators Invest in high-growth, high-margin healthcare niches Invest in automation and other operational efficiency projects Maintain dividend 17
Slide 18: Innovation
Innovation D-FlexTM: unique disposable injection pen ensuring that patients select only the intended dose(s)
Slide 19: CliX DROP
CliXTM DROP Redefines dental application tools providing a competitive advantage Precision One perfect drop, every time Innovation of Use From conventional bottle to iconic simplicity Sustainability & Control Less waste, more control, intuitive use IP protected High entry barrier 19
Slide 20: CliX DROP: more than an applicator, an ecosystem
CliXTM DROP More than an applicator: an ecosystem Adhesive Liquids Gels Secured storage Multi-use with valve 2mL with consistent delivery 20
Slide 21: Vented G-System
Vented G-System A proprietary next-generation delivery platform for bone graft materials Engineered for precision and efficiency, this system enables legal manufacturers of surgical products to significantly accelerate production workflows, offering a clear and sustainable competitive edge Initial p
Slide 22: Outlook
Outlook 2025 transition year • Revised top line 2025 guidance: revenue decline similar to that seen in H1 2025 on a FX adjusted basis • Confirmed 2025 profitability guidance: adjusted EBITDA margin 18% to 19% Confirmed mid-term guidance (3 years) • Revenue CAGR above 4% • Adjusted EBITDA margin abov
Slide 23: Q&A
Q&A René Willi, CEO Jennifer Dean, CFO
Slide 24: Your Investor Relations contact
Your Investor Relations contact Domenico Truncellito Head Corporate Communications & Investor Relations Phone: +41 41 723 73 57 E-mail: investorrelations@medmix.com medmix Group AG Neuhofstrasse 20 6340 Baar Switzerland